NanoLogix is a rapid diagnostic and petri plate focused biotech company. Its N-Assay is designed to detect and identify bacteria for which an antibody exists, and can also determine the level of antibiotic sensitivity and resistance.
The company said they were contacted in February and finalized the deal in late October, with a purchase order being issued in late November.
Nanologix began customizing the assay this month and billed the company for 1/3rd of the contract amount, according to a press release.
The identity of the contracting company and the terms and details of the contract were not released.